Follow the news and you know: Scientists are more than just chipping away at cancer. They are kicking down the barricades. Cell therapies are, at long last, delivering lasting remissions in a few indications. Small molecules and antibodies with new mechanisms of action – sometimes in clever combination – are raising the bar, making cancer more of a chronic and tolerable disease. Underlying information on gene mutations, dysregulated protein networks and the tumor microenvironment provide a vivid glimpse of malignancy at the molecular level, and a wellspring for new therapeutic ideas. Much of this progress is occurring here on the West Coast. Hear from the leaders in Big Biotech, venture capital, and emerging startups at The Seattle Cancer Summit, March 5. All proceeds go to the Mt. Everest Climb to Fight Cancer campaign at Fred Hutchinson Cancer Research Center. 

Confirmed speakers:

• James Sabry, Senior Vice President, Genentech Partnering
• Rob Hersberg, EVP, Celgene
• Clay Siegall, Co-founder and CEO, Seattle Genetics
• Sunil Agarwal, President of R&D, Juno Therapeutics
• Chad Robins, CEO, Adaptive Biotechnologies
• Peter Thompson, Private Equity Partner, OrbiMed
• Andy Schwab, Managing Partner, 5AM Ventures
• Julie Sunderland, Managing Director, Biomatics Capital
• Thong Le, CEO, Accelerator Life Science Partners
• Andrew Allen, CEO, Gritstone Oncology
• Joe Victor, CEO, RareCyte
• Colleen Delaney, Co-founder and CMO, Nohla Therapeutics
• Jay Shendure, Professor of Genome Sciences, University of Washington; Director of Brotman Baty Institute for Precision Medicine
• Niki Robinson, Vice President of Business Development and Strategy, Fred Hutch
• Mitch Gold, Executive Chair and CEO, Alpine Immune Sciences
• Ali Tehrani, CEO, Zymeworks
• Sam Blackman, SVP, Silverback Therapeutics
• Monica Beam, SVP, Alexandria Venture Investments